ストックスクリーナーアプリを入手
585.50
1.82%
10.44
プレマーケット:
589.99
4.49
+0.77%
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Harbor Investment Advisory LLC Sells 523 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT - MSN
Integrity Alliance LLC. Makes New $579,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight - Yahoo Finance
Regeneron’s Garetosmab May Become Second Drug For Rare Bone Disease FOP - insights.citeline.com
Risk Off: Can Regeneron Pharmaceuticals Inc. expand its profit marginsTrade Performance Summary & AI Based Buy/Sell Signal Reports - خودرو بانک
Regeneron Pharmaceuticals (REGN): Evaluating Valuation Following Breakthrough Phase 3 Allergy Drug Results - simplywall.st
Regeneron (REGN) Rises Amid Positive Obesity Treatment Study - GuruFocus
Regeneron Pharmaceuticals (REGN) Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies - uk.finance.yahoo.com
Regeneron, Elf Beauty, Eli Lilly - TradingView
Regeneron Touts Positive Data From Phase 3 StudyRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Regeneron’s garetosmab shows 90% reduction in bone lesions in FOP patients By Investing.com - Investing.com South Africa
Oruka Therapeutics, Regeneron, natgas companies - TradingView
Regeneron’s garetosmab shows 90% reduction in bone lesions in FOP patients - Investing.com Australia
‘Prolific’ Regeneron won’t stop with phase III FOP data drop - BioWorld MedTech
Regeneron (REGN) Reports Promising Results in Obesity Treatment Trial - GuruFocus
Birch Allergy Market Trends Point to Steady Growth Ahead by 2034, - openPR.com
Regeneron Pharmaceuticals Reports Positive 26-Week Results from Phase 2 COURAGE Trial Combining Semaglutide with Trevogrumab for Obesity Treatment - Quiver Quantitative
Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD - MarketScreener
92.6% Fat Loss Achievement: Regeneron's Triple Therapy Outperforms Standard GLP-1 Weight Loss in Phase 2 Trial - Stock Titan
Regeneron's rare bone disorder drug succeeds in late-stage trial - Reuters
Regeneron drug reduces errant bone growth in ultra-rare skeletal condition - statnews.com
Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint - MarketScreener
Regeneron announces primary endpoint met in Phase 3 OPTIMA trial - TipRanks
Regeneron's Garetosmab Hits Main Endpoint in Phase 3 Study - MarketScreener
Regeneron succeeds in late-stage trial for rare connective disorder therapy - Seeking Alpha
Regeneron's bone disorder treatment succeeds in late-stage trial - Reuters
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation - The Manila Times
Regeneron's genetic disorder treatment meets main goal of late-stage trial - MarketScreener
99% Bone Formation Prevention: Regeneron's Breakthrough Drug Shows Promise for Ultra-Rare FOP Disease - Stock Titan
Woodstock Corp Has $4.21 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
4,105 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by AG2R LA Mondiale Gestion D Actifs - MarketBeat
Focus Partners Wealth Sells 3,238 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
S P Trends: What is Regeneron Pharmaceuticals Inc. s 5 year growth outlookQuarterly Trade Summary & Weekly Top Gainers Alerts - خودرو بانک
Aug Momentum: Is Regeneron Pharmaceuticals Inc trading at a discountJuly 2025 News Drivers & Community Consensus Stock Picks - خودرو بانک
Aug Drivers: Will Regeneron Pharmaceuticals Inc. stock recover after earningsJuly 2025 Sector Moves & Precise Trade Entry Recommendations - خودرو بانک
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - MarketScreener
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals - Benzinga
Regeneron Pharmaceuticals (REGN) Releases Results From EMPOWER-Lung 3 trial - MSN
Portfolio Recap: What is Regeneron Pharmaceuticals Inc. s 5 year growth outlookJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - خودرو بانک
RMR Wealth Builders Acquires 593 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
GuoLine Advisory Pte Ltd Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Central Pacific Bank Trust Division Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Acadian Asset Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MBB Public Markets I LLC Purchases New Shares in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Voleon Capital Management LP - MarketBeat
Surprises Report: Can Regeneron Pharmaceuticals Inc. reach all time highs this year - خودرو بانک
Bispecific Antibodies in Oncology Market Forecast to Surge Over the Next Decade | DelveInsight - Yahoo Finance
Custom watchlist performance reports with Regeneron Pharmaceuticals Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
DOJ Probe and Eylea Sales Pressures Could Be a Game Changer for Regeneron Pharmaceuticals (REGN) - simplywall.st
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? - The Globe and Mail
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Voya Investment Management LLC - MarketBeat
BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN) - Insider Monkey
Portfolio Update: Can Regeneron Pharmaceuticals Inc reach all time highs this yearPortfolio Performance Report & Risk Managed Investment Signals - خودرو بانک
First Hawaiian Bank Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Geneos Wealth Management Inc. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN - Defense World
Key metrics from Regeneron Pharmaceuticals Inc.’s quarterly dataMarket Trend Summary & Consistent Income Trade Ideas - newser.com
Intech Investment Management LLC Has $5.06 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Advisors Capital Management LLC Sells 801 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Strs Ohio Takes $21.81 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
UniSuper Management Pty Ltd Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teza Capital Management LLC Sells 898 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
2.06%
1.53%
大文字化:
|
ボリューム (24 時間):